<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961661</url>
  </required_header>
  <id_info>
    <org_study_id>CF pilot</org_study_id>
    <nct_id>NCT01961661</nct_id>
  </id_info>
  <brief_title>Probiotics on Intestinal Inflammation in Cystic Fibrosis</brief_title>
  <official_title>Effect of Probiotics on Intestinal Inflammation and Microflora in Cystic Fibrosis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF) is a complex systemic disease that mainly involves the respiratory and
      gastrointestinal (GI) tracts. The polymicrobial community composition of respiratory and GI
      tracts is influenced by both genetic and environmental factors. Children with CF may harbor
      an abnormal intestinal microflora, because of altered Cystic fibrosis transmembrane
      conductance regulator (CFTR) function and heavy drug load (antibiotics, pancreatic enzymes
      and acid suppressors). The investigators previously demonstrated that intestinal inflammation
      is highly frequent in CF children, being a major feature of intestinal involvement. In
      addition, specific probiotics significantly improved airway and GI inflammation in a
      preliminary trial. The aim of the study is to characterize intestinal and respiratory
      microflora in CF patients and to investigate the effects of daily Lactobacillus GG (LGG)
      supplementation on both GI and airway microflora and the eventual relationship between
      probiotic assumption and clinical and inflammation markers. The aim is to study the effect of
      microflora modification on intestinal and extraintestinal inflammation to eventually improve
      the quality of life of CF patients, who often suffer from intestinal and respiratory
      progressive disease, through a non invasive intervention consisting in the supplementation of
      probiotic bacteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modification of intestinal inflammation</measure>
    <time_frame>baseline and after 1 month of treatment</time_frame>
    <description>Evaluation of intestinal inflammation at baseline and 1 month after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in intestinal microflora composition</measure>
    <time_frame>baseline and 1 month after treatment</time_frame>
    <description>Modification of Fluorescent in Situ Hybridization profile of intestinal microflora at baseline and 1 month of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus rhamnosus GG 5x10^9 colony forming units (CFU)per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrins</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus rhamnosus GG</intervention_name>
    <description>Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 capsule/die for 1 month</description>
    <arm_group_label>probiotic</arm_group_label>
    <other_name>LGG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 cps/die for 12 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CF documented by sweat chloride test over 60 mmol/L and confirmed by
             genotype analysis with the presence of F508del/F508del or F508del/other;

          -  Boys and girls between 2 and 16 years of age;

          -  Clinical stability at enrolment, defined as no clinical evidence of acute
             exacerbation, no modifications in the therapeutic regimen and no hospitalization in
             the last 2 weeks;

          -  Pancreatic insufficiency;

          -  Basal Forced expiratory volume 1 second (FEV1) above 50% of predicted value.

        Exclusion Criteria

          -  Colonization of respiratory tract with Burkholderia cepacia spp.;

          -  Steroid therapy within one month before enrolment;

          -  Pregnancy and fertile women taking oral contraceptives;

          -  Parenteral or oral antibiotics therapy within 2 weeks before enrolment;

          -  Regular assumption of probiotics;

          -  Regular assumption of azythromycin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pediatrics University Federico II</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bruzzese E, Raia V, Spagnuolo MI, Volpicelli M, De Marco G, Maiuri L, Guarino A. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr. 2007 Jun;26(3):322-8. Epub 2007 Mar 13.</citation>
    <PMID>17360077</PMID>
  </reference>
  <reference>
    <citation>Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola V, Guarino A. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther. 2004 Oct 1;20(7):813-9.</citation>
    <PMID>15379842</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Alfredo Guarino</investigator_full_name>
    <investigator_title>Full professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>intestinal inflammation</keyword>
  <keyword>intestinal microflora</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

